The Samsung Biologics Rights Offering: Who Is Actually Funding This $2.2 Billion Bet

Samsung Biologics just announced it will raise 3 trillion won — about $2.2 billion by issuing new shares. The money has one main job: buy a Swiss company called PolyPeptide Group, which makes the peptide ingredients inside the wave of GLP-1 weight-loss and diabetes drugs reshaping the pharmaceutical industry.

The headline number is big. The structure of the raise is where the actual economics live. And once you look at who holds Samsung Biologics' shares and how the rights offering works, the picture changes from "this company is flooding the market with new stock" to "two Korean conglomerate subsidiaries are writing most of the check to buy their way into a scarce manufacturing bottleneck."

That is not necessarily the same story. It is worth untangling.

A rights offering is the corporate-finance equivalent of a private dinner where the guests who are already seated get first refusal on new seats at a discount. Existing shareholders get the right to buy new shares proportional to their current holding — in this case at 1.322 million won per share, about a 15% discount to the reference price. If they decline, the unsubscribed shares go to a general public offering, and if those don't fill, underwriting banks are on the hook.

Samsung Biologics is issuing 2.27 million new shares against an existing base of roughly 46.3 million. That is about 5% dilution. The discount is real, but it is a limited discount on a limited slice. (Twenty percent of the new shares are reserved for employees under Korean law, so the pool available to existing shareholders is smaller than the headline number suggests.)

Here is where the plumbing matters: Samsung C&T and Samsung Electronics together hold 74.3% of Samsung Biologics' stock. That means the vast majority of the new-share subscription — and the vast majority of the dilution cost — falls on two related corporate shareholders, not on the public float.

The public market holds roughly a quarter of the company. A 5% dilution, applied to a quarter of the share base, leaves minority shareholders absorbing perhaps 1.25% of effective dilution. The remaining dilution cost is an internal transfer within the Samsung group — money moving from Samsung C&T and Samsung Electronics' treasuries into Samsung Biologics to buy a Swiss factory.

The stock fell about 5.7% on the announcement. Dilution anxiety is a reflexive market response, even when the math is modest and the majority of it is absorbed by insiders who want the deal to happen. (The market also did not love the general tone of the Korean index that day, but Samsung Biologics' drop was notably wider than its neighbors.)

So what are they buying?

PolyPeptide Group is a specialized peptide contract manufacturer — a CDMO, like Samsung Biologics itself, but one that makes short chains of amino acids instead of the large antibody proteins that Samsung has spent its career perfecting. PolyPeptide was spun out of the Swiss pharma company Ferring in 1996 and has produced more than 1,000 therapeutic peptides over its history. It operates in Sweden, Belgium, France, the U.S., and India.

Its financial profile is what you'd expect from a specialized manufacturer riding a demand wave: €389 million in revenue for 2025, up 15.6% from the prior year. EBITDA jumped 84% to €46.8 million, with the margin expanding to 12% from 7.5%. The improvement came from higher volumes at a new large-scale facility in Belgium and better product mix. PolyPeptide is guiding for another 20–25% revenue growth in 2026 and margins climbing into the mid-to-high teens.

But here is the number that looks odd at first glance: Samsung is paying roughly $1.8 billion for a company that generates about $420 million in revenue and €47 million in EBITDA. That is about 4x revenue and north of 30x EBITDA — multiples more suited to a software company than a capital-intensive chemical manufacturer.

The basic point is that Samsung is not buying a revenue stream. It is buying time.

Peptide manufacturing capacity is physically scarce, and it cannot be created quickly. A new commercial peptide production line takes roughly two years to build, then another 18 to 24 months to qualify for regulated markets. From the moment you sign a contract to the moment you ship product that a regulator will accept, you are looking at three to four years.

Meanwhile, the demand side is accelerating on a timeline that has nothing to do with manufacturing speed. Novo Nordisk and Eli Lilly are building multi-billion-dollar peptide facilities themselves. But their capacity is for their own drugs. The pharma industry is full of companies that want to launch GLP-1 and other peptide therapies and need someone to make them. That someone — a qualified, proven peptide CDMO — is not easy to find.

PolyPeptide has the track record (1,000+ peptides), the geographic footprint, and, crucially, the approved facilities that already exist. Samsung Biologics has the scale, balance sheet, and global biopharma customer base. Combining them creates a multi-modality CDMO — one that can manufacture antibodies, antibody-drug conjugates, and peptides under one roof for a single customer.

In practice, this is an old competitive playbook: acquire the thing you cannot build fast enough, before the market creates enough supply to compress your pricing power. The GLP-1 demand surge is the catalyst, but the mechanism is the same as any bottleneck play — you buy the queue before it shortens.

The question is not whether peptide capacity is valuable. The question is whether Samsung is overpaying for it.

That depends on three things.

First, whether the GLP-1 and broader peptide boom sustains its pace. PolyPeptide's own 2025 results suggest it is real: revenue growth of 15.6% at constant currency, operating leverage kicking in, and management guiding for acceleration, not deceleration. The company's mid-term target is to double its 2023 revenue by 2028, with EBITDA margins approaching 25%. Those are not easy targets to hit, but the demand pipeline they describe appears genuine.

Second, whether Samsung Biologics can actually integrate a European peptide specialist into its Korean-dominated operating model. PolyPeptide has a decentralized footprint (Sweden, Belgium, France, the U.S., India) and a 70-year heritage of decentralized, relationship-driven pharma manufacturing. Samsung Biologics runs a highly standardized, volume-optimized model built around massive plants in Incheon, Korea. These are not incompatible, but integration is a separate risk from acquisition. A CDMO's value is partly in its execution credibility with pharma clients; a botched merger can erode that faster than a slow market can.

Third, and this is the one that the rights-offering structure makes visible: Samsung Biologics already has plenty of cash from its own operations. In the second quarter of 2026 alone, it generated 586 billion won in operating profit — about $420 million in a single quarter. The full-year 2025 run rate was roughly 4.5 trillion won in revenue with operating margins in the mid-40s. The company chose a rights offering rather than using internal cash or taking on debt.

That choice is interesting. Using equity, even concentrated equity among majority shareholders, signals that management wants to preserve its balance sheet for something else — likely the capacity expansion that is the second bucket of the raise. The remaining 295 billion won of the offering is earmarked for Plants 6 through 8 at Samsung's Bio Campus II, which will push total antibody capacity from the current 845,000 liters to 1.385 million liters by 2032.

The rights offering preserves cash while funding both the acquisition and the build. It is a clean structure — no debt covenants, no interest cost, no dilution shock to the public float. It costs the Samsung group some equity, but the Samsung group wanted this deal. The alignment is the point.

For a U.S. investor, Samsung Biologics is not easy to own directly. It trades on the Korean exchange under ticker 207940.KS. You would need a brokerage that gives you access to KOSPI stocks. Its current market cap is roughly $51 billion, and it is the dominant listed pure-play CDMO outside the U.S.

The investment case the rights offering clarifies is not whether Samsung Biologics is a good business — its margins, capacity utilization, and contract backlog already establish that. The investment case the rights offering clarifies is how aggressively Samsung's majority owners are willing to deploy capital to extend the business into peptides.

The 30x EBITDA price for PolyPeptide is expensive by manufacturing standards. It is defensible only if you believe peptide capacity will remain constrained for the three to five years it would take a competitor to build an equivalent facility. If GLP-1 demand normalizes or if enough generic peptide capacity floods the market, that premium evaporates. If it does not, Samsung Biologics becomes the only CDMO that can credibly serve a pharma client's antibody, ADC, and peptide needs simultaneously — and that is worth paying for.

The rights offering itself is not the risk. The 5% dilution is modest, and most of it lands on shareholders who are funding it voluntarily because they want the deal done. The risk is whether the peptide scarcity trade justifies the entry price. Samsung Biologics' owners think it does, and they are putting their own equity behind that bet. That is the kind of conviction that is worth noticing — even if you do not share the conclusion.